Skip to main content
OpenTrials
Completed

NCT Number: NCT01228175

Effectiveness of Varenicline: Testing Individual Differences

The study will evaluate the effectiveness of smoking cessation using Varenicline versus placebo. Effectiveness will be measured by the average number of cigarettes smoked per smoking day for up to 36 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Addiction

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

The Mind Research Network

Albuquerque, New Mexico, 87106, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 yrs to 55 yrs
  • smoker

Exclusion criteria

  • Medical Contraindications

Treatment and study plan

Placebo

Drug

25mg look alike riboflavin tablets to match active study medication.

Other names: riboflavin

Varenicline

Drug

Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily

Other names: Chantix

Primary outcomes

  1. Cigarettes Per Smoking Day

    Time frame: up to 36 weeks

    The number of cigarettes smoked were assessed only on a "smoking day", i.e., when a participant smoked at least 1 cigarette. Data was recorded each day for up to 36 weeks.

Sponsors and collaborators

Lead sponsor

The Mind Research Network

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: Varenicline

Important dates

Study start
2010
Primary completion
2015
Study completion
2016
First posted
Oct 26, 2010
Registry last updated
May 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.